

COMPANY Profile

A publication of the Purdue Research Park



Today Novilytic's technology addresses the problem of preparing blood specimens for analysis.

About Novilytic, LLC

Novilytic launched in 2013 to focus on fast, disposable sample preparation technology for biological samples. The company evolved from Intellimmune, a company that specialized in analytical, contract services. Novilytic will retain and advance technology from Intellimmune on Vitamin D analysis, which will now be offered with Novilytic's sample preparation technology. Today Novilytic's technology addresses the problem of preparing blood specimens for analysis. The current venipuncture approach requires a certified phlebotomist, access to a qualified centrifuge, and a mechanism to store and ship refrigerated blood samples. Novilytic has introduced and commercialized the Noviplex™ Plasma Preparation Card. This card requires just a few drops of blood and automatically extracts plasma which can be quickly dried for shipment. The card does not require trained personnel, centrifuges, cooling or even any power source. Blood specimens can be obtained anytime and anywhere. The dried plasma is suitable for analysis by such advanced techniques as LC/MS, MALDI-TOF, ICP/MS, ELISA, and QPCR.

Significant Events

The Noviplex™ Plasma Preparation Card, a plasma separation and collection technology was introduced in January 2014, representing the first commercial product to produce a consistent volume of plasma without the need for centrifugation or any power source. In 2015 Novilytic began shipping its second product, the Noviplex™ Duo Plasma Preparation Card that generates two equivalent plasma samples from a single application of blood.

Over the past three years, Novilytic received \$1.1 million in NIH Small Business Innovation Research (SBIR) funding for Phase I and Phase II research to develop Noviplex™ technology and associated applications involving detection of Vitamin D and other biomarkers.

An independent judging panel and editors of R&D Magazine recently selected Noviplex technology for its R&D Top 100 award as being among the 100 most technologically significant products introduced during 2014.

FACTS & FIGURES

Established

Founded in 2013 by four partners. Fred E. Regnier and Jiri Adamec are distinguished researchers in academia holding a variety of patents involving the application of analytical chemistry to the biosciences. Timothy and Edward Woenker are principal equity and management partners in Chematics, Inc., an established medical device company based in North Webster, Indiana with market reach in both domestic and international markets.

Key Personnel

Fred Regnier Ph.D, Chief Executive Officer
Jiri Adamec Ph.D, Chief Scientific Officer
Jin Hee Kim, Ph.D, Director of Analytical Services
Timothy E. Woenker, President
Edward W. Woenker, Treasurer
Tim Schlabach, Ph.D., Director of Sales and Marketing.

Contact

Kurz Technology Center, 1281 Win Hentschel Blvd., West Lafayette, IN 47906; info@novilytic.com or 800-588-9799

KEY LEADERSHIP



Fred Regnier Ph.D
CEO



Jiri Adamec Ph.D
CSO



Edward Woenker
Treasurer



Timothy Woenker
President



Jin Hee Kim, Ph.D
Director of Analytical Services



Tim Schlabach
Director of Sales and Marketing